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OBJECTIVE— Greater accumulation of visceral fat is strongly linked to risk of cardiovascular
disease. However, elevated waist circumference by itself does not always identify individuals
with increased visceral fat.
RESEARCH DESIGN AND METHODS— We examined 375 subjects with type 2
diabetes from the CHICAGO cohort for presence of hypertriglyceridemic waist phenotype (waist
circumference90 cm in men or85 cm in women, in conjunction with a plasma triglyceride
concentration of177 mg/dl) to determine its usefulness for identifying subjects with increased
amounts of visceral fat. We divided subjects into three groups: group 1 (low waist circumference
and low triglycerides; waist circumference90 cm in men or85 cm in women and triglyceride
177 mg/dl, n  18), group 2 (high waist circumference and low triglycerides; waist circum-
ference 90 cm in men or 85 cm in women and triglycerides 177 mg/dl, n  230), and
group 3 (high waist circumference and high triglycerides; waist circumference90 cm in men
or 85 cm in women and triglycerides 177 mg/dl, n  127).
RESULTS— Subjects in group 3 had significantly higher visceral fat (P 0.0001), A1C (P
0.01), and coronary artery calcium (P 0.05) compared with group 2, despite similar age, BMI,
and waist circumference. The relationship of the phenotype to atherosclerosis, however, was
attenuated by adjustment for HDL cholesterol, triglyceride-rich lipoprotein cholesterol, apoli-
poprotein B, or LDL particle number.
CONCLUSIONS— The presence of hypertriglyceridemic waist phenotype in subjects with
type 2 diabetes identifies a subset with greater degree of visceral adiposity. This subset also has
greater degree of subclinical atherosclerosis that may be related to the proatherogenic lipoprotein
changes.
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D espite the strong association of obe-sity, especially abdominal obesity,to metabolic and cardiovascular
disease, not all obese individuals carry the
same metabolic and cardiovascular risk
(1,2). The metabolic syndrome (a cluster
of metabolic abnormalities that include
glucose intolerance, central obesity, dys-
lipidemia, and hypertension) has been
used to identify individuals at high risk
for type 2 diabetes and cardiovascular dis-
ease (3,4). A hypertriglyceridemic waist
phenotype defined as an elevated waist
circumference (90 cm in men or 85
cm in women) along with an elevated
plasma triglyceride concentration (de-
fined as a level 177 mg/dl) has been
proposed and shown to be a stronger
marker of cardiovascular risk and a better
predictor of cardiovascular disease than
the metabolic syndrome in nondiabetic
subjects (5,6). Deposition of visceral fat
may be most closely linked to the meta-
bolic and cardiovascular risk associated
with both the metabolic syndrome and the
hypertriglyceridemic waist phenotype (6).
The CHICAGO cohort is a well-
characterized group of men and women
with type 2 diabetes who had measure-
ments of abdominal fat depots by com-
puted tomography (CT) and coronary
artery calcium (CAC) by electron-beam
tomography (7–9). We evaluated the
prevalence of hypertriglyceridemic waist
phenotype in this cohort and report its
usefulness for identifying subjects with
diabetes who have higher levels of visceral
fat. We further examined the metabolic
and cardiovascular impact of this pheno-
type in subjects with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Subjects for the current
analysis were non-Hispanic white (n 
246) and non-Hispanic black participants
(n  129) in the CHICAGO trial, a pro-
spective study of the effects of pioglita-
zone compared with glimepiride on
carotid intima-media thickness in sub-
jects with type 2 diabetes recruited from
28 clinical sites in Chicago (7–9). The de-
tails of the study have been previously re-
ported (7–9). Data included in this report
were obtained prior to randomization to
treatment groups. All subjects were
asymptomatic for coronary artery disease
at baseline. The study was approved by
central and local institutional review
board committees, and all participants
provided written informed consent. All
subjects underwent measurements of
height, weight, and waist and hip circum-
ference by a trained nurse at the baseline
visit. Waist circumference was mea-
sured at the level of umbilicus to the
nearest 0.1 cm. BMI was calculated as
weight in kilograms divided by the
square of height in meters.
Subjects underwent an abdominal CT
scan for determination of visceral adipose
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tissue (VAT) and subcutaneous adipose
tissue (SAT), as previously described (9).
Fasting blood samples were obtained at
the baseline visit for measurements of
A1C, lipid panel, and LDL particle num-
ber by previously described techniques
(7,8). Triglyceride-rich lipoprotein (TRL)
cholesterol was calculated by subtracting
the directly measured values for LDL and
HDL cholesterol from total cholesterol.
Non-HDL cholesterol was calculated by
subtracting the directly measured values
for HDL cholesterol from total choles-
terol. CAC was determined using previ-
ously described techniques (8).
Statistical methods
The cohort was divided into three pheno-
types based on criteria for hypertriglycer-
idemic waist: group 1 included subjects
with waist circumference90 cm in men
or85 cm in women and triglyceride lev-
els 177 mg/dl, group 2 included sub-
jects with waist circumference90 cm in
men or 85 cm in women and triglycer-
ide levels 177 mg/dl, and group 3 (hy-
pertriglyceridemic waist) included
subjects with waist circumference 90
cm in men or 85 cm in women and
triglyceride levels177 mg/dl (5). There
was only one subject who had an elevated
triglyceride level and low waist circumfer-
ence. Analyses were performed with in-
clusion of that subject in group 2 (since he
had intermediate phenotype) but were
also repeated after exclusion of that sub-
ject, which did not impact any of our
results.
Log transformation of the data was
performed when necessary to achieve ho-
mogeneity of variance. Age, BMI, and
waist circumference were compared us-
ing ANCOVA with Bonferonni post hoc
analysis to evaluate the differences among
the three groups. Categorical variables
among the three groups were compared
using 2 analysis. Differences in LDL,
HDL, and TRL cholesterol and VAT, SAT,
total abdominal fat (TAT), A1C, and CAC
scores were examined using general linear
model with Bonferonni analysis to com-
pare the differences among the three
groups. These analyses were also adjusted
for age, BMI, sex, diabetes treatment,
years of smoking, insulin use, duration of
diabetes, and use of statins. Analyses for
VAT, SAT, and TAT were also performed
separately for each sex. Since racial differ-
ences in VAT have been reported, with
blacks having lower amount of VAT com-
pared with whites (10), we examined the
impact of race on the usefulness of the
hypertriglyceridemic waist phenotype for
identifying subjects with increased vis-
ceral fat. To do this, we examined the re-
lationship between the phenotype and
abdominal fat distribution separately for
each race and performed a test of hetero-
geneity for the relation between race and
hypertriglyceridemic waist phenotype
and body fat distribution. The analyses
for the relationship between body distri-
bution and CAC score were further ad-
justed for A1C, HDL cholesterol, TRL
cholesterol, non-HDL cholesterol, apoli-
poprotein (apo) B, and LDL particle num-
ber. Analyses were performed using the
11.0 PC package of SPSS statistical soft-
ware (SPSS, Chicago, IL). A P 0.05 was
considered significant.
RESULTS— The cohort was divided
into three groups based on the criteria for
hypertriglyceridemic waist (5). The base-
line characteristics of the three groups are
summarized on Table 1. The mean age for
group 1 was 67 years, for group 2 was 61
years, and for group 3 was 60 years. Sub-
jects in group 1 were older compared with
subjects in groups 2 and 3 (P  0.002).
The average BMI for group 1 was 24.7 
2.8 kg/m2, for group 2 was 33.0  4.9
kg/m2, and for group 3 was 32.5  4.6
kg/m2. The average waist circumference
for group 1 was 81.4 5.0 cm, for group
2 was 109.1  12.0 cm, and for group 3
was 108.6 10.9 cm. Subjects in group 1
were leaner (P  0.0001) and had lower
waist circumference (P  0.0001) com-
pared with subjects in groups 2 and 3.
There were no differences in age, BMI, or
waist circumference between subjects in
groups 2 and 3.
Thirty-nine percent of subjects in
group 1 were men compared with 61% in
group 2 and 65% in group 3, but these
differences were not statistically signifi-
cant (Table 1). There were no differences
in smoking status, duration of diabetes, or
statin use among the three groups (Table
1). There were differences in diabetes
therapy among the three groups, with a
higher percentage of subjects in group 3
not taking any diabetes medication (21%)
compared with group 1 (11%) and group
2 (12%). Furthermore, fewer subjects in
group 3 were taking insulin (3%) com-
pared with group 1 (22%) and with group
Table 1—Baseline characteristics of study participants based on hypertriglyceridemic waist
phenotypes
Group 1 Group 2 Group 3
n 18 230 127
Age (years) 67  10* 61  8 60  7
BMI (kg/m2) 24.7  2.8 33.0  4.9† 32.5  4.6†
Waist circumference (cm) 81.4  5.0 109.1  12.0† 108.6  10.9†
Duration of type 2 diabetes (months) 121  159 94  83 86  79
A1C (%) 7.0  0.8 7.3  0.9 7.6  1.1‡
Sex (%)
Men 39 61 65
Women 61 39 35
Smoking (%)
Current 17 15 15
Former 50 48 54
Never 33 37 31
Diabetes therapy (%)
None 11 12 21§
Sulfonylurea 17 16 15
Metformin 28 25 36§
Sulfonylurea and metformin 22 34 25§
Insulin 22 13 3§
Statin use (%)
On statin 50 53 60
No statin 50 47 40
Data are means SD or percent. Group 1 (low waist circumference and low triglycerides; waist circumfer-
ence90 cm in men or85 cm in women and triglycerides177 mg/dl); group 2 (high waist circumfer-
ence and low triglycerides; waist circumference 90 cm in men or 85 cm in women and triglycerides
177 mg/dl, n 230); and group 3 (high waist circumference and high triglycerides; waist circumference
90 cm in men or85 cm in women and triglyceride177 mg/dl, n 127). *P 0.05 vs. groups 2 and
3; †P  0.0001 vs. group 1; ‡P  0.01 vs. groups 1 and 2; §P  0.01 vs. group 2.
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2 (13%), and more subjects in group 3
were taking metformin-only therapy
(36%) compared with groups 1 (28%)
and 2 (25%).
Differences in lipid profile are dem-
onstrated in Table 2. Level of TRL choles-
terol was higher in group 3 compared
with group 1 (P  0.0001) and group 2
(P 0.0001) (Table 2). Level of non-HDL
cholesterol and apoB were higher in
group 3 compared with group 1 (P 
0.001 for both non-HDL and apoB) and
group 2 (P  0.0001 for both non-HDL
and apoB) (Table 2). There were no dif-
ferences in LDL cholesterol levels among
the three groups (Table 2). HDL choles-
terol levels were higher in group 1 com-
pared with group 2 (P 0.01) and group
3 (P  0.0001). HDL cholesterol levels
were also significantly higher in group 2
compared with group 3 (P 0.0001) (Ta-
ble 2). LDL particle number was higher in
group 3 (1,709  563) compared with
group 2 (1,369  500; P  0.0001) and
with group 1 (1,254  450; P  0.001)
(data not shown).
Table 3 summarizes the differences in
body fat distribution among the three
groups. Subjects in group 1 had signifi-
cantly lower TAT and VAT compared
with subjects in both groups 2 and 3 (P
0.0001 for all comparisons), while SAT
did not differ among the three groups in
adjusted analyses. Despite similar BMI
and waist circumference in groups 2 and
3 (Table 1), subjects in group 2 had sig-
nificantly lower VAT (P  0.0001) com-
pared with those in group 3 (Table 3).
These differences in VAT and TAT among
groups persisted after adjustment for
A1C, apoB levels, LDL particle number,
HDL cholesterol, TRL cholesterol, and
non-HDL cholesterol. Furthermore, sim-
ilar results were obtained if each sex was
examined separately. Since the racial
makeup of groups 2 and 3 were different
in our sample (42% of group 2 are black
vs. 16% of group 3) and race has been
reported to influence abdominal fat dis-
tribution (10), we examined the differ-
ences in VAT among groups separately for
each race. For whites and blacks exam-
ined separately, subjects in group 3 had
greater amounts of visceral fat compared
with those in group 2, even after adjust-
ment for age, BMI, smoking years, dura-
tion of diabetes, sex, and statin use
(similar to findings for the combined
group). Furthermore, tests of heterogene-
ity were not significant for the interaction
between race, hypertriglyceridemic waist,
and visceral fat. These results indicate that
the hypertriglyceridemic waist phenotype
can be useful for identifying both white
and black subjects with increased visceral
fat.
Subjects in group 3 had the highest
A1C level (7.6  1.1) compared with
group 2 (7.3 0.9; P 0.01) and group
1 (7.0 0.8; P 0.01), after adjustment
for age, BMI, diabetes therapy, insulin
use, duration of diabetes, years of smok-
ing, and statin use. CAC scores were
higher in group 3 (255  77) compared
with group 2 (218 48) (P 0.03), after
adjustments for age, BMI, diabetes ther-
apy, insulin use, duration of diabetes,
years of smoking, and statin use. There
was no difference in CAC between group
1 (202 168) and the other two groups,
which is most likely related to the small
sample size. The difference in CAC scores
between groups 2 and 3 remained signif-
icant after addition of A1C to the model
(P  0.05, data not shown). However,
differences in CAC scores between groups
2 and 3 were no longer present after fur-
ther adjustment for HDL cholesterol (P
0.1), TRL cholesterol (P 0.6), non-HDL
cholesterol (P  0.2), apoB levels (P 
0.2), or LDL particle number (P  0.3)
(data not shown). HDL cholesterol was a
predictor of CAC in a model adjusted for
age, BMI, diabetes therapy, insulin use,
duration of diabetes, years of smoking,
and statin use. However, its predictive
value was lost after addition of hypertri-
glyceridemic waist phenotype or TRL
cholesterol to the model. TRL cholesterol
was a strong independent predictor of
CAC even after addition of hypertriglyc-
eridemic waist phenotype and HDL cho-
lesterol to the model (P 0.004, data not
shown).
CONCLUSIONS— In this study, we
found that in a large well-characterized
cohort of obese subjects with type 2 dia-
betes, the presence of elevated triglycer-
ides, along with an elevated waist
circumference (both defined as proposed
for the hypertriglyceridemic waist pheno-
type in nondiabetic subjects) (5,6), iden-
tifies a subgroup with higher amount of
Table 2—Comparison of lipid profile based on hypertriglyceridemic phenotype
Group
Triglycerides
(mg/dl)
LDL
cholesterol
(mg/dl)
HDL
cholesterol
(mg/dl)
TRL
cholesterol
(mg/dl)
Non-HDL
cholesterol
(mg/dl)
ApoB
(mg/dl)
1 (n  18) 114  381 109  156 61  58 19  17 129  34 80  30
2 (n  230) 117  111 110  45 51  17* 19  17 130  30 80  30
3 (n  127) 270  185† 119  75 42  23† 40  23† 159  45‡ 100  30‡
Data are means SD. Group 1 (low waist circumference and low triglyceride; waist circumference90 cm
in men or 85 cm in women and triglycerides 177 mg/dl); group 2 (high waist circumference and low
triglyceride; waist circumference90 cm in men or85 cm in women and triglycerides177 mg/dl, n
230); and group 3 (high waist circumference and high triglyceride; waist circumference90 cm in men or
85 cm in women and triglycerides177 mg/dl, n 127). Analysis is adjusted for age, BMI, sex, diabetes
treatment, years of smoking, insulin use, duration of diabetes, and use of statins. TRL cholesterol was
calculated by subtracting the directly measured values for LDL and HDL cholesterol from total cholesterol.
Non-HDL cholesterol was calculated by subtracting the directly measured values for HDL cholesterol from
total cholesterol. *P  0.01 vs. group 1; †P  0.0001 vs. groups 1 and 2; ‡P  0.01 vs. groups 1 and 2.
Table 3—Body fat distributions based on hypertriglyceridemic waist phenotypes
Group
TAT (cm3) TAT (cm3) VAT (cm3) VAT (cm3) SAT (cm3)
SAT
(cm3)
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
1 (n  18) 173  47 292  780 62  24 95  54 112  36 204  62
2 (n  230) 330  101 316  85* 128  57 117  60* 205  84 204  71
3 (n  127) 337  85 340  94* 149  51 150  67† 194  61 195  73
Data are means SD and adjusted meansSD with P value only reported for adjusted means. Group 1 (low
waist circumference and low triglyceride; waist circumference 90 cm in men or 85 cm in women and
triglycerides177 mg/dl); group 2 (high waist circumference and low triglyceride; waist circumference90
cm in men or 85 cm in women and triglycerides 177 mg/dl, n  230); and group 3 (high waist
circumference and high triglyceride; waist circumference 90 cm in men or 85 cm in women and
triglycerides177 mg/dl, n 127). Analyses for TAT, VAT, and SAT are adjusted for age, BMI, sex, diabetes
treatment, years of smoking, insulin use, duration of diabetes, and use of statins. *P 0.0001 vs. group 1;
†P  0.0001 vs. groups 1 and 2.
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visceral fat. The relationship remained af-
ter adjustment for multiple factors includ-
ing age, sex, BMI, duration of diabetes,
years of smoking, diabetes therapy, insu-
lin, A1C, and statin use.
The existence of benign obesity or
overweight and obese individuals who are
metabolically healthy is well recognized
(1,2). A recent study indicates that among
the National Health and Nutrition Exam-
ination Survey cohort, 51% of overweight
and 32% of the obese adults are metabol-
ically healthy. Furthermore, in this study,
waist circumference was not different be-
tween the two obese subgroups (metabol-
ically healthy versus those with metabolic
abnormalities) (1). The relation of waist
circumference to abdominal adiposity is
complicated as this measurement corre-
lates well with the amount of total abdom-
inal fat but cannot distinguish between
subcutaneous and visceral adiposity. Nu-
merous epidemiologic, as well as physio-
logic, studies have suggested that visceral
fat is more strongly associated with meta-
bolic risk factors as well as cardiovascular
disease than subcutaneous abdominal fat
(6,11). For instance, individuals matched
for subcutaneous abdominal fat, but with
different degrees of visceral fat, have been
shown to have markedly different levels
of insulin resistance and glucose tolerance
(12). Surgical removal of abdominal sub-
cutaneous fat in obese subjects did not
result in metabolic improvements or ben-
eficial changes in cardiovascular risk fac-
tors (13). Conversely, removal of visceral
fat has led to metabolic improvements
(14). Adipose tissue has been shown to
secrete a number of inflammatory media-
tors (15), and visceral adipose tissue has
been shown to secrete higher quantities of
these inflammatory cytokines (15,16).
Hence, visceral fat may be the distinguish-
ing factor separating metabolically
healthy obese individuals from obese in-
dividuals who are not metabolically
healthy.
Several investigators, including us,
have demonstrated that an increase in the
size of visceral fat depot is associated with
metabolic syndrome, inflammation, dys-
lipidemia, and coronary artery disease
(17–20). Measurement of visceral fat de-
pot requires imaging techniques such as
CT or magnetic resonance imaging that
are not practical screening tools for the
general population due to cost and radia-
tion exposure. The concept of a hypertri-
glyceridemic waist has been proposed by
Despres and colleagues (5,6) for identify-
ing viscerally obese individuals at risk for
cardiovascular disease. This group advo-
cates that a fasting plasma triglyceride
level of 177 mg/dl in conjunction with
abdominal obesity (waist circumference
90 cm in men and 85 cm in women)
is a better predictor of metabolic and car-
diovascular risk than the metabolic syn-
drome (5,6). In a study by another group
of investigators (21), among the National
Cholesterol Education Program (NCEP)
criteria for metabolic syndrome, waist cir-
cumference and triglyceride levels best
correlated to visceral adiposity and insu-
lin resistance. The results of the current
study confirm that simultaneous mea-
surement of fasting triglycerides and waist
circumference is a useful approach for
identifying subjects with the greatest
amount of visceral fat even among obese
subjects with type 2 diabetes.
CAC measured by electron-beam to-
mography is a measure of total coronary
atherosclerosis that has been validated by
coronary angiogram (22). The amount of
CAC has been shown to correlate well
with the amount of atherosclerotic plaque
in patients with type 2 diabetes (23). In
large prospective studies, CAC has been
found to be a significant predictor of car-
diovascular disease in symptomatic and
asymptomatic subjects (24). In the cur-
rent study, we demonstrate that subjects
with greater degree of visceral adiposity
based on hypertriglyceridemic waist, in-
dependent of many factors including gly-
cemic control, had the highest CAC score.
The difference in CAC between groups 2
and 3 was significant but perhaps not as
large as might be expected given the more
profound metabolic abnormalities in the
latter group (Table 2). This could be re-
lated to an overall higher prevalence of
CAC in type 2 diabetes compared with
nondiabetic subjects (25). Nonetheless,
subjects in group 3 had significantly
higher amount of CAC compared with
those in group 2, though both groups had
similar BMI and waist circumference.
However, the relationship between the
hypertriglyceridemic phenotype and
CAC was not present after adjustments
for HDL cholesterol, non-HDL choles-
terol, TRL cholesterol, LDL particle num-
ber, or apoB. In a previous study of the
CHICAGO cohort (8), our group has
reported that visceral adipose tissue
predicted CAC but not after adjustment
for TRL cholesterol. Due to the cross-
sectional nature of this study, we are not
able to make any conclusions regarding
the causal nature of the associations
observed.
In this study, A1C was highest in the
subset with hypertriglyceridemic waist
(group 3). These differences were present
even after adjustment for a number of
confounders including age, sex, BMI, di-
abetes therapy, duration of diabetes, years
of smoking, and use of insulin and statins.
A higher percentage of subjects with hy-
pertriglyceridemic waist phenotype were
treated with metformin, and fewer were
treated with either insulin or sulfonylurea
compared with those with lower triglyc-
eride levels and elevated waist circumfer-
ence. The reasons for these differences in
therapy are not clear; however, all of the
analyses in our report were adjusted for
diabetes therapy and insulin use.
In summary, our results indicate that
even in the presence of type 2 diabetes, an
elevated waist circumference, by itself,
does not identify subjects with the highest
accumulation of visceral fat. Addition of
fasting triglyceride levels to waist circum-
ference is a simple and inexpensive
method for clinicians to identify those
with greatest amount of visceral fat and
thus greatest metabolic and cardiovascu-
lar risk. In diabetes, the association of the
hypertriglyceridemic waist phenotype
with coronary atherosclerosis may be re-
lated to the proatherogenic lipoprotein
changes associated with the phenotype.
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